Storia in 2 fonti

Compass Pathways Highlights Data, Backs 2027 Launch Timeline - Compass Pathways (NASDAQ:CMPS)

Compass Pathways reported positive 26-week Phase 3 COMP360 data for treatment-resistant depression as its FDA filing remains on track.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

Compass Pathways reported positive 26-week Phase 3 COMP360 data for treatment-resistant depression as its FDA filing remains on track.

Compass Pathways is on track to complete its NDA filing for treatment-resistant depression by the end of the year despite a stock drop.